Morningstar

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer ...

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on ...
Investing

Circle Q3 2025 presentation: revenue hits $740M amid platform expansion and market share gains

Circle’s presentation highlighted the company’s growing market share in the stablecoin ecosystem. USDC’s share of total stablecoins in circulation increased from 23% in Q3 2024 to 29% in Q3 2025, ...
Morningstar

Circle Pharma Announces Upcoming Poster Presentation Highlighting the Anti-tumor Potential of Cyclin D1 RxL Inhibition at the AACR-NCI-EORTC International Conference on ...

Cyclin D1 is overexpressed in certain solid tumors and hematologic malignancies. In these cancers, the cyclin D1/CDK4 complex drives cell proliferation by binding to the tumor suppressor ...
VentureBeat

Preclinical Data on Circle Pharma’s CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the ...
Benzinga.com

Circle Internet Group Q3 2025 Earnings Call Transcript

Circle Internet Group Inc (NYSE:CRCL) reported financial results for the third quarter before the market open on Wednesday. The transcript from the earnings call has been provided below. Ladies and ...
VentureBeat

Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, today announced an upcoming poster presentation at the AACR-NCI-EORTC ...